Digestio Aparatua
Espezialitatea
María Isabel
Vera Mendoza
María Isabel Vera Mendoza-rekin lankidetzan egindako argitalpenak (21)
2024
-
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Therapeutic Advances in Gastroenterology, Vol. 17
-
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612
2023
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
2022
-
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Biomedicines, Vol. 10, Núm. 3
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2018
-
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 8, pp. 839-851
2016
-
Efectos adversos de los inhibidores de la bomba de protones: revisión de evidencias y posicionamiento de la Sociedad Española de Patología Digestiva
Revista Española de Enfermedades Digestivas, Vol. 108, Núm. 4, pp. 207-224
-
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab
Biochemical Pharmacology, Vol. 122, pp. 33-41
2014
-
Disease severity in familial cases of IBD
Journal of Crohn's and Colitis, Vol. 8, Núm. 3, pp. 234-239
-
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293
2013
-
Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal (2013)
Gastroenterologia y Hepatologia, Vol. 36, Núm. 3, pp. 127-146
-
Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients
Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410
2012
-
Long-term durability of response to adalimumab in Crohn's disease
Inflammatory Bowel Diseases, Vol. 18, Núm. 4, pp. 685-690
2011
-
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
Alimentary Pharmacology and Therapeutics, Vol. 33, Núm. 3, pp. 340-348
-
Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients
Alimentary Pharmacology and Therapeutics, Vol. 34, Núm. 5, pp. 544-554